116 related articles for article (PubMed ID: 15135484)
1. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma.
Brink I; Hentschel M; Bley TA; Walch A; Mix M; Kleimaier M; Moser E; Imdahl A
Eur J Surg Oncol; 2004 Jun; 30(5):544-50. PubMed ID: 15135484
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
3. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
4. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
5. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
7. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
Smithers BM; Couper GC; Thomas JM; Wong D; Gotley DC; Martin I; Harvey JA; Thomson DB; Walpole ET; Watts N; Burmeister BH
Dis Esophagus; 2008; 21(2):151-8. PubMed ID: 18269651
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
11. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
[TBL] [Abstract][Full Text] [Related]
12. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.
Brücher BL; Weber W; Bauer M; Fink U; Avril N; Stein HJ; Werner M; Zimmerman F; Siewert JR; Schwaiger M
Ann Surg; 2001 Mar; 233(3):300-9. PubMed ID: 11224616
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer.
Kato H; Kuwano H; Nakajima M; Miyazaki T; Yoshikawa M; Masuda N; Fukuchi M; Manda R; Tsukada K; Oriuchi N; Endo K
Am J Surg; 2002 Sep; 184(3):279-83. PubMed ID: 12354600
[TBL] [Abstract][Full Text] [Related]
15. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
[TBL] [Abstract][Full Text] [Related]
16. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
[TBL] [Abstract][Full Text] [Related]
17. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
18. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
20. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Sloof GW
Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
